AbbVie Tries to Develop Hep C Regimen Without Interferon | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Patient Enrollment Started in the Phase II HELIX-2 Clinical Trial

Back to News Homepage
Next

FDA Approves 2nd Drug for Treatment of Chronic HCV

AbbVie Tries to Develop Hep C Regimen Without Interferon

The Editors at Hepatitis Central
December 4, 2013

Print this page

Find out about AbbVie Inc. and its progress in developing an oral treatment for Hepatitis C.

AbbVie Cites Positives In Hepatitis C Treatment

November 21, 2013

Michael Novinson

AbbVie Inc. said its oral treatment for hepatitis C showed about 96 percent of patients had no detectable levels of the virus after 12 weeks.

The late-stage trial was designed to evaluate a regimen that fuses two experimental drugs developed by AbbVie with an antiviral drug that has been used a hepatitis C treatment for decades. The 631 patients enrolled in the trial were diagnosed with the genotype 1 variant of the infection, which accounts for some 70 percent of hepatitis C cases.

Continue reading this entire article:
http://www.wbjournal.com/article/20131121/NEWS01/131129991/1002

No Comments - be the first!
Share
Share
Previous

Patient Enrollment Started in the Phase II HELIX-2 Clinical Trial

Back to News Homepage
Next

FDA Approves 2nd Drug for Treatment of Chronic HCV

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.